Silence Therapeutics plc (SLN)
NASDAQ: SLN · Real-Time Price · USD
6.23
+0.06 (0.97%)
Jun 8, 2026, 4:00 PM EDT - Market closed
Silence Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 5.66 | 11.28 | 121.33 | 68.79 | 66.32 | 99.42 |
Short-Term Investments | 64.42 | 73.84 | 26 | - | 19.75 | - |
Cash & Short-Term Investments | 70.08 | 85.11 | 147.33 | 68.79 | 86.07 | 99.42 |
Cash Growth | -48.67% | -42.23% | 114.18% | -20.08% | -13.43% | 86.74% |
Accounts Receivable | - | - | 0.97 | 0.29 | 1.11 | 0.45 |
Other Receivables | 22.22 | 22.01 | 24.4 | 22.44 | 18 | 9.39 |
Total Trade Receivables | 22.22 | 22.01 | 25.37 | 22.73 | 19.11 | 9.84 |
Other Current Assets | 10.56 | 11.54 | 14.66 | 11.63 | 11.79 | 7.46 |
Total Current Assets | 102.85 | 118.66 | 187.37 | 103.15 | 116.97 | 116.72 |
Net Property, Plant & Equipment | 1.54 | 1.75 | 1.98 | 2.31 | 2.66 | 2.63 |
Other Intangible Assets | 0.25 | 0.29 | 0.31 | 0.36 | 0.39 | 0.03 |
Goodwill | 10.36 | 10.62 | 9.39 | 9.98 | 9.69 | 10.26 |
Long-Term Investments | - | - | - | - | 0.34 | 0.41 |
Other Long-Term Assets | 0.13 | 0.13 | 3.59 | 3.65 | - | - |
Total Assets | 115.12 | 131.44 | 202.64 | 119.45 | 130.05 | 130.05 |
Accounts Payable | 10.37 | 13.36 | 16.4 | 15.54 | 15.28 | 14.58 |
Current Portion of Leases | 0.09 | 0.09 | 0.12 | 0.23 | 0.54 | 0.19 |
Unearned Revenue | - | 0.17 | 0.31 | 6.57 | 10.72 | 5.74 |
Total Current Liabilities | 10.46 | 13.61 | 16.82 | 22.34 | 26.55 | 20.51 |
Long-Term Leases | 0.04 | 0.07 | - | 0.12 | - | - |
Other Long-Term Liabilities | 55.22 | 55.45 | 51.79 | 75 | - | - |
Total Long-Term Liabilities | 55.26 | 55.53 | 51.79 | 75.12 | - | - |
Total Liabilities | 65.72 | 69.14 | 68.61 | 97.46 | 26.55 | 20.51 |
Common Stock | -10.29 | -10.29 | -10.29 | -8.85 | 6.52 | 6.07 |
Additional Paid-in Capital | -620.01 | -617.56 | -609.56 | -455.77 | 336.16 | 304.82 |
Accumulated Other Comprehensive Income | 3.37 | 2.98 | 11.78 | 10.73 | - | - |
Retained Earnings | 577.53 | 562.57 | 474.04 | 431.89 | -318.5 | -301.45 |
Shareholders' Equity | -49.4 | -62.3 | -134.02 | -21.99 | 26.7 | 11.53 |
Total Liabilities & Equity | 115.12 | 131.44 | 202.64 | 119.45 | 53.25 | 32.03 |
Total Debt | 0.14 | 0.16 | 0.12 | 0.35 | 0.54 | 0.19 |
Net Cash (Debt) | 69.94 | 84.95 | 147.22 | 68.44 | 85.53 | 99.24 |
Net Cash Growth | -17.67% | -42.29% | 115.09% | -19.98% | -13.81% | 88.04% |
Net Cash Per Share | 1.48 | 1.80 | 3.18 | 1.84 | 2.66 | 3.35 |
Book Value | -49.4 | -62.3 | -134.02 | -21.99 | 26.7 | 11.53 |
Book Value Per Share | -1.05 | -1.32 | -2.90 | -0.59 | 0.83 | 0.39 |
Tangible Book Value | -60.01 | -73.21 | -143.73 | -32.34 | 16.63 | 1.23 |
Tangible Book Value Per Share | -1.27 | -1.55 | -3.11 | -0.87 | 0.52 | 0.04 |